We can’t show the full text here under this license.
Safety and effectiveness of weekly semaglutide compared to extra oral diabetes medicines in Japanese people with poorly controlled type 2 diabetes
Updated
Abstract
88.0% of participants receiving semaglutide reported adverse events, compared to 71.7% with an additional oral antidiabetic drug.
- Semaglutide 0.5 mg and 1.0 mg significantly reduced mean glycated hemoglobin (HbA1c) by 1.7% and 2.0%, respectively, compared to a 0.7% reduction with the additional oral antidiabetic drug.
- Body weight decreased by 1.4 kg and 3.2 kg in the semaglutide groups, while participants receiving the additional oral antidiabetic drug experienced a 0.4-kg weight increase.
- More than 80% of semaglutide-treated participants achieved an HbA1c concentration below 7.0%, meeting the target set by the Japanese Diabetes Society.
- Gastrointestinal adverse events were the most frequent in semaglutide groups but typically mild or moderate and diminished over time.
- No new safety issues were identified with semaglutide treatment.
Simplified
Key numbers
1.7%
Reduction in HbA1c
Change in HbA1c with semaglutide 0.5 mg vs additional OAD
3.2 kg
Body weight change
Mean weight change with semaglutide 1.0 mg vs additional OAD
88.0%
Adverse events incidence
Proportion of participants reporting TEAEs with semaglutide 1.0 mg